Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP12 | P39900 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | UBE2N | P61088 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3719656 | 0.96 | POLB (0.61) | ALDH1A1POLBRAB9ATDP1MMP8 | |
| SCHEMBL7226660 | 0.92 | POLB (0.62) | ALDH1A1POLBRAB9ATDP1MMP8 | |
| SCHEMBL7226664 | 0.92 | POLB (0.62) | ALDH1A1POLBRAB9ATDP1MMP8 | |
| SCHEMBL12995467 | 0.81 | POLB (0.53) | ALDH1A1POLBRAB9AUBE2N | |
| SCHEMBL1381814 | 0.81 | POLB (0.53) | ALDH1A1POLBRAB9AUBE2NHTT | |
| SCHEMBL2977278 | 0.78 | ALDH1A1 (0.72) | ALDH1A1RAB9AHTT | |
| SCHEMBL1385016 | 0.78 | ALDH1A1 (0.72) | ALDH1A1RAB9AHTT | |
| SCHEMBL6971945 | 0.76 | POLB (0.50) | ALDH1A1POLBRAB9ATDP1 | |
| SCHEMBL23838661 | 0.75 | UBE2N (0.57) | RAB9ATDP1UBE2NNPC1 | |
| SCHEMBL22633392 | 0.75 | TDP1 (0.68) | ALDH1A1POLBRAB9ATDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017491-A1 | COMPOUND INHIBITING YAP-TEAD BINDING, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING COMPOUND AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-20 | — | — | US | disclosed |
| US-7731949-B2 | — | — | 2010-06-08 | — | — | US | disclosed |
| CN-101668528-A | Compounds and methods for treatment of hcv | XTL BIOPHARMACEUTICALS LTD | 2010-03-10 | — | — | CN | disclosed |
| EP-2076264-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF HCV | XTL Biopharmaceuticals LTD (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090041723-A1 | Compounds and methods for treatment of HCV | XTL BIOPHARMACEUTICALS LTD. (IL) | 2009-02-12 | — | — | US | disclosed |
| WO-2008048589-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF HCV | XTL BIOPHARMACEUTICALS LTD (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017491-A1 | COMPOUND INHIBITING YAP-TEAD BINDING, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING COMPOUND AS ACTIVE INGREDIENT | YAP1, TEAD2, TEAD1 | ALDH1A1 2937/4885POLB 4108/4885RAB9A 643/4885 |
| US-20090041723-A1 | Compounds and methods for treatment of HCV | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1835/4885POLB 486/4885RAB9A 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.